Literature DB >> 28511236

Long-term outcomes after endoscopic ultrasound-guided ablation of pancreatic cysts.

Jun-Ho Choi1, Dong Wan Seo2, Tae Jun Song2, Do Hyun Park2, Sang Soo Lee2, Sung Koo Lee2, Myung-Hwan Kim2.   

Abstract

Background and study aims The aim of this study was to investigate the long-term outcomes after endoscopic ultrasound (EUS)-guided pancreatic cyst ablation. Patients and methods In a single-center, prospective study, 164 patients with pancreatic cysts underwent EUS-guided cyst ablation using ethanol with paclitaxel. The inclusion criteria were as follows: unilocular or oligolocular cysts; clinically indeterminate cysts that required EUS fine-needle aspiration; and/or cysts that grew during the observation period. Treatment response was classified as complete resolution, partial resolution, or persistent cyst, with < 5 %, 5 % - 25 %, and 25 % of the original cyst volume, respectively. Results The median largest diameter of the cyst was 32 mm and the median volume was 17.1 mL. Based on cyst fluid analysis there were 71 mucinous cystic neoplasms, 16 serous cystic neoplasms, 11 intraductal papillary mucinous neoplasms, 3 pseudocysts, and 63 indeterminate cysts. Sixteen treated patients (9.8 %) had adverse events (1 severe, 4 moderate, and 11 mild). Treatment response was as follows: complete resolution in 114 (72.2 %), partial resolution in 31 (19.6 %), and persistent cysts in 13 (8.2 %). Twelve of the 13 patients with persistent cysts underwent surgery. During clinical and imaging follow-up (median 72 months, interquartile range 50 - 85 months) of the 114 patients with complete resolution, only two patients (1.7 %) showed cyst recurrence. Based on multivariate analysis, the absence of septa (odds ratio [OR] 7.12, 95 % confidence interval [CI] 2.72 - 18.67) and cyst size less than 35 mm (OR 2.39, 95 %CI 1.11 - 5.16) predicted complete resolution. Conclusion Among patients with pancreatic cysts in whom complete resolution was achieved after EUS-guided cyst ablation, 98.3 % remained in remission at 6-year follow-up. Unilocular form and small cyst size were predictive of complete resolution. This treatment approach may be an effective and durable alternative to surgery.Trial registered at ClinicalTrials.gov (NCT 00689715). © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28511236     DOI: 10.1055/s-0043-110030

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  15 in total

1.  Endoscopic Ultrasound and Related Technologies for the Diagnosis and Treatment of Pancreatic Disease - Research Gaps and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Authors:  Linda S Lee; Dana K Andersen; Reiko Ashida; William R Brugge; Mimi I Canto; Kenneth J Chang; Suresh T Chari; John DeWitt; Joo Ha Hwang; Mouen A Khashab; Kang Kim; Michael J Levy; Kevin McGrath; Walter G Park; Aatur Singhi; Tyler Stevens; Christopher C Thompson; Mark D Topazian; Michael B Wallace; Sachin Wani; Irving Waxman; Dhiraj Yadav; Vikesh K Singh
Journal:  Pancreas       Date:  2017 Nov/Dec       Impact factor: 3.327

2.  Pancreatic Cysts after Endoscopic Ultrasonography-Guided Ethanol and/or Paclitaxel Ablation Therapy: Another Mimic of Pancreatic Pseudocysts.

Authors:  Soyeon An; You-Na Sung; Sung Joo Kim; Dong-Wan Seo; Sun-Young Jun; Seung-Mo Hong
Journal:  Pathobiology       Date:  2021-08-26       Impact factor: 4.342

3.  Incidence and Risk Factors for New-Onset Diabetes Mellitus After Surgical Resection of Pancreatic Cystic Lesions: A MarketScan Study.

Authors:  Stephen A Firkins; Phil A Hart; Kyle Porter; ChienWei Chiang; Jordan M Cloyd; Mary Dillhoff; Luis F Lara; Andrei Manilchuk; Georgios I Papachristou; Timothy M Pawlik; Allan Tsung; Darwin L Conwell; Somashekar G Krishna
Journal:  Pancreas       Date:  2022-07-19       Impact factor: 3.243

4.  Clinical outcomes of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions compared with the natural course: a propensity score matching analysis.

Authors:  Jin Ho Choi; Sang Hyub Lee; Young Hoon Choi; Jinwoo Kang; Woo Hyun Paik; Dong-Won Ahn; Ji Kon Ryu; Yong-Tae Kim
Journal:  Therap Adv Gastroenterol       Date:  2018-03-07       Impact factor: 4.409

Review 5.  Endoscopic ultrasound-guided injective ablative treatment of pancreatic cystic neoplasms.

Authors:  Chen Du; Ning-Li Chai; En-Qiang Linghu; Hui-Kai Li; Xiu-Xue Feng
Journal:  World J Gastroenterol       Date:  2020-06-21       Impact factor: 5.742

6.  Large cystic lymphangioma of pancreas mimicking mucinous neoplasm: case report with a review of histological differential diagnosis.

Authors:  Mohammad Hossein Anbardar; Neda Soleimani; Arian Aminzadeh Vahedi; Seyed Ali Malek-Hosseini
Journal:  Int Med Case Rep J       Date:  2019-09-03

7.  Duodenal Stricture due to Necrotizing Pancreatitis following Endoscopic Ultrasound-Guided Ethanol Ablation of a Pancreatic Cyst: A Case Report.

Authors:  Jung Won Chun; Sang Hyub Lee; Jin Ho Choi; Woo Hyun Paik; Ji Kon Ryu; Yong-Tae Kim
Journal:  Clin Endosc       Date:  2019-07-04

Review 8.  Therapeutic EUS: New tools, new devices, new applications.

Authors:  Barbara Braden; Vipin Gupta; Christoph Frank Dietrich
Journal:  Endosc Ultrasound       Date:  2019 Nov-Dec       Impact factor: 5.628

9.  Future Perspectives on Endoscopic Ultrasonography-Guided Therapy for Pancreatic Neoplasm.

Authors:  Woo Hyun Paik; Sang Hyub Lee; Sunguk Jang
Journal:  Clin Endosc       Date:  2018-05-18

10.  Initial experience with EUS-guided microbiopsy forceps in diagnosing pancreatic cystic lesions: A multicenter feasibility study (with video).

Authors:  Bojan Kovacevic; John Gásdal Karstensen; Roald Flesland Havre; Khanh Do-Cong Pham; Marc Giovannini; Emanuele Dabizzi; Paolo Arcidiacono; Erwin Santo; Enrique Vazquez Sequeiros; Pia Klausen; Charlotte Vestrup Rift; Jane Preuss Hasselby; Anders Toxværd; Evangelos Kalaitzakis; Carsten Palnæs Hansen; Peter Vilmann
Journal:  Endosc Ultrasound       Date:  2018 Nov-Dec       Impact factor: 5.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.